3237 related articles for article (PubMed ID: 28438806)
1. Emerging Affinity-Based Proteomic Technologies for Large-Scale Plasma Profiling in Cardiovascular Disease.
Smith JG; Gerszten RE
Circulation; 2017 Apr; 135(17):1651-1664. PubMed ID: 28438806
[TBL] [Abstract][Full Text] [Related]
2. Application of Large-Scale Aptamer-Based Proteomic Profiling to Planned Myocardial Infarctions.
Jacob J; Ngo D; Finkel N; Pitts R; Gleim S; Benson MD; Keyes MJ; Farrell LA; Morgan T; Jennings LL; Gerszten RE
Circulation; 2018 Mar; 137(12):1270-1277. PubMed ID: 29222138
[TBL] [Abstract][Full Text] [Related]
3. Aptamer-Based Proteomic Profiling Reveals Novel Candidate Biomarkers and Pathways in Cardiovascular Disease.
Ngo D; Sinha S; Shen D; Kuhn EW; Keyes MJ; Shi X; Benson MD; O'Sullivan JF; Keshishian H; Farrell LA; Fifer MA; Vasan RS; Sabatine MS; Larson MG; Carr SA; Wang TJ; Gerszten RE
Circulation; 2016 Jul; 134(4):270-85. PubMed ID: 27444932
[TBL] [Abstract][Full Text] [Related]
4. High throughput and accurate serum proteome profiling by integrated sample preparation technology and single-run data independent mass spectrometry analysis.
Lin L; Zheng J; Yu Q; Chen W; Xing J; Chen C; Tian R
J Proteomics; 2018 Mar; 174():9-16. PubMed ID: 29278786
[TBL] [Abstract][Full Text] [Related]
5. Optomechanical devices for deep plasma cancer proteomics.
Kosaka PM; Calleja M; Tamayo J
Semin Cancer Biol; 2018 Oct; 52(Pt 1):26-38. PubMed ID: 28867489
[TBL] [Abstract][Full Text] [Related]
6. [Advances in high-throughput proteomic analysis].
Wu Q; Sui X; Tian R
Se Pu; 2021 Feb; 39(2):112-117. PubMed ID: 34227342
[TBL] [Abstract][Full Text] [Related]
7. Multi-component immunoaffinity subtraction chromatography: an innovative step towards a comprehensive survey of the human plasma proteome.
Pieper R; Su Q; Gatlin CL; Huang ST; Anderson NL; Steiner S
Proteomics; 2003 Apr; 3(4):422-32. PubMed ID: 12687610
[TBL] [Abstract][Full Text] [Related]
8. Discovery of Candidate Biomarkers.
Wiktorowicz JE; Soman KV
Adv Exp Med Biol; 2016; 919():443-462. PubMed ID: 27975230
[TBL] [Abstract][Full Text] [Related]
9. IgY14 and SuperMix immunoaffinity separations coupled with liquid chromatography-mass spectrometry for human plasma proteomics biomarker discovery.
Shi T; Zhou JY; Gritsenko MA; Hossain M; Camp DG; Smith RD; Qian WJ
Methods; 2012 Feb; 56(2):246-53. PubMed ID: 21925605
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular proteomics: tools to develop novel biomarkers and potential applications.
Arab S; Gramolini AO; Ping P; Kislinger T; Stanley B; van Eyk J; Ouzounian M; MacLennan DH; Emili A; Liu PP
J Am Coll Cardiol; 2006 Nov; 48(9):1733-41. PubMed ID: 17084242
[TBL] [Abstract][Full Text] [Related]
11. Rat plasma proteomics: effects of abundant protein depletion on proteomic analysis.
Linke T; Doraiswamy S; Harrison EH
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Apr; 849(1-2):273-81. PubMed ID: 17188586
[TBL] [Abstract][Full Text] [Related]
12. Strategies for plasma proteomic profiling of cancers.
Omenn GS
Proteomics; 2006 Oct; 6(20):5662-73. PubMed ID: 16991194
[TBL] [Abstract][Full Text] [Related]
13. Recent progress in selected reaction monitoring MS-driven plasma protein biomarker analysis.
Chiu CL; Randall S; Molloy MP
Bioanalysis; 2009 Jul; 1(4):847-55. PubMed ID: 21083142
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular-related proteins identified in human plasma by the HUPO Plasma Proteome Project pilot phase.
Berhane BT; Zong C; Liem DA; Huang A; Le S; Edmondson RD; Jones RC; Qiao X; Whitelegge JP; Ping P; Vondriska TM
Proteomics; 2005 Aug; 5(13):3520-30. PubMed ID: 16052623
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of multiprotein immunoaffinity subtraction for plasma proteomics and candidate biomarker discovery using mass spectrometry.
Liu T; Qian WJ; Mottaz HM; Gritsenko MA; Norbeck AD; Moore RJ; Purvine SO; Camp DG; Smith RD
Mol Cell Proteomics; 2006 Nov; 5(11):2167-74. PubMed ID: 16854842
[TBL] [Abstract][Full Text] [Related]
16. Depletion of abundant plasma proteins and limitations of plasma proteomics.
Tu C; Rudnick PA; Martinez MY; Cheek KL; Stein SE; Slebos RJ; Liebler DC
J Proteome Res; 2010 Oct; 9(10):4982-91. PubMed ID: 20677825
[TBL] [Abstract][Full Text] [Related]
17. Approaching clinical proteomics: current state and future fields of application in fluid proteomics.
Apweiler R; Aslanidis C; Deufel T; Gerstner A; Hansen J; Hochstrasser D; Kellner R; Kubicek M; Lottspeich F; Maser E; Mewes HW; Meyer HE; Müllner S; Mutter W; Neumaier M; Nollau P; Nothwang HG; Ponten F; Radbruch A; Reinert K; Rothe G; Stockinger H; Tarnok A; Taussig MJ; Thiel A; Thiery J; Ueffing M; Valet G; Vandekerckhove J; Verhuven W; Wagener C; Wagner O; Schmitz G
Clin Chem Lab Med; 2009; 47(6):724-44. PubMed ID: 19527139
[TBL] [Abstract][Full Text] [Related]
18. Biomarker discovery from the plasma proteome using multidimensional fractionation proteomics.
Lee HJ; Lee EY; Kwon MS; Paik YK
Curr Opin Chem Biol; 2006 Feb; 10(1):42-9. PubMed ID: 16418010
[TBL] [Abstract][Full Text] [Related]
19. Mixed-mode ion exchange-based integrated proteomics technology for fast and deep plasma proteome profiling.
Xue L; Lin L; Zhou W; Chen W; Tang J; Sun X; Huang P; Tian R
J Chromatogr A; 2018 Aug; 1564():76-84. PubMed ID: 29935814
[TBL] [Abstract][Full Text] [Related]
20. Performance evaluation of affinity ligands for depletion of abundant plasma proteins.
Kullolli M; Warren J; Arampatzidou M; Pitteri SJ
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Nov; 939():10-6. PubMed ID: 24090752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
